Skip to content

Author

Seiko Ikezu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Suppression of Tau-tubulin kinase 1 mitigates tau phosphorylation, and Aβ mediated neurotoxicity via altered kinase network.

Tau-tubulin kinase-1 (TTBK1) is a neuron-specific serine/threonine tau kinase that is highly expressed in the entorhinal and hippocampal regions and phosphorylates microtubule-associated protein tau at sites relevant to Alzheimer's disease (AD), thereby contributing to early tau pathology. Targeting TTBK1 can be a prom...

Kayo Yukawa, Satoshi Muraoka, Samtani Grace et al. · 0 citations
Review Open access Sep 2026

Nucleic acid therapeutics in neurodegenerative disorders: emerging technologies and clinical landscape

This review summarizes three major NAT platforms—antisense oligonucleotides, small interfering RNAs, and aptamers—by highlighting their mechanisms of action, design principles to enhance their biodistribution, durability, and safety, and emerging novel delivery strategies for CNS targeting.

Masahiro Ohara, S. Ishigaki, Jonathan K. Watts et al. · 0 citations
Open access Sep 2026

Human iPSC models reveal APOE4-induced microglial remodeling and extracellular vesicle dysregulation in AD pathogenesis

Summary The apolipoprotein E ε4 (APOE4) allele is the strongest genetic risk factor for late-onset Alzheimer’s disease (AD), yet the mechanistic underpinnings by which it alters human microglial function remain poorly understood. Here, we utilize CRISPR/Cas9-engineered isogenic human induced pluripotent stem cell-deriv...

Y. You, Son N. Nguyen, Sean D. Mann et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.